Last reviewed · How we verify
Prednisone 6 weeks
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammatory or autoimmune conditions (specific indication not provided in source data), Immunosuppression in various systemic inflammatory disorders.
At a glance
| Generic name | Prednisone 6 weeks |
|---|---|
| Also known as | Glucocorticoid |
| Sponsor | Xinqiao Hospital of Chongqing |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / General anti-inflammatory |
| Phase | FDA-approved |
Mechanism of action
Prednisone acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression of inflammatory mediators. It decreases production of cytokines (IL-1, IL-6, TNF-α), reduces immune cell activation and proliferation, and stabilizes lysosomal membranes to limit inflammatory cell degranulation. The 6-week course suggests treatment of an acute inflammatory or autoimmune condition requiring short-term immunosuppression.
Approved indications
- Acute inflammatory or autoimmune conditions (specific indication not provided in source data)
- Immunosuppression in various systemic inflammatory disorders
Common side effects
- Insomnia / sleep disturbance
- Increased appetite / weight gain
- Mood changes / irritability
- Hyperglycemia
- Hypertension
- Gastrointestinal upset
- Immunosuppression / increased infection risk
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder (EARLY_PHASE1)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (NA)
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone 6 weeks CI brief — competitive landscape report
- Prednisone 6 weeks updates RSS · CI watch RSS
- Xinqiao Hospital of Chongqing portfolio CI